Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XPro1595 in Alzheimer's Disease (OLE)
NCT05522387Phase 2Terminated
- Sponsor
- INmune Bio Inc.
- Start
- Feb 2023
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
A Phase 2 trial of pegipanermin in Alzheimer's disease (AD), sponsored by INmune Bio Inc.. Started Feb 2023; status: terminated.
02
Drugs
pegipanermin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05522387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05522387.